Age-dependent biochemical dysfunction in skeletal muscle of triple-transgenic mouse model of Alzheimer's disease

Current Alzheimer Research

Volumn 12, Issue 2, 2015, Pages 100-115

  Monteiro Cardoso, Vera F ^a   Castro, Marisa ^a   Oliveira, M M ^a   Moreira, Paula I ^b,c   Peixoto, Francisco ^d   Videira, Romeu A ^a  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Alzheimer's disease; Amyloid p; Lipidomics; Mitochondrial bioenergetics; Phospholipase A2; Phospholipids; Skeletal muscle

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE DIPHOSPHATE; AMYLOID BETA PROTEIN[1-40]; ARACHIDONIC ACID; FATTY ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; PHOSPHOLIPID; AMYLOID BETA PROTEIN; CATALASE; PEPTIDE FRAGMENT; PHOSPHATIDAL ETHANOLAMINES; PHOSPHATIDYLINOSITOL; PLASMALOGEN;

AGE; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BIOENERGY; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MITOCHONDRION; MOUSE; MYOSITIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; AGING; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; MALE; METABOLISM; MITOCHONDRIAL MEMBRANE;

ACETYLCHOLINESTERASE; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ARACHIDONIC ACID; CATALASE; DISEASE MODELS, ANIMAL; FATTY ACIDS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; MUSCLE, SKELETAL; PEPTIDE FRAGMENTS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASES A2; PLASMALOGENS;

EID: 84924862255     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150204124852     Document Type: Article

References (70)

1. [1] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1): a006189 (2011).
2. [2] Arai Y, Suzuki A, Mizuguchi M, Takashima S. Developmental and aging changes in the expression of amyloid precursor protein in Down syndrome brains. Brain Dev-Jpn 19(4): 290-4 (1997).
3. [3] Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, et al. Elevated A beta and apolipoprotein E in A beta PP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 6(5): 430-9 (2000).
4. [4] Burns JM, Johnson DK, Watts A, Swerdlow RH, Brooks WM. Reduced Lean Mass in Early Alzheimer Disease and Its Association With Brain Atrophy. Arch Neurol-Chicago 67(4): 42833 (2010).
5. [5] Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical-Diagnosis of Alzheimers-Disease - Report of the Nincds-Adrda Work Group under the Auspices of Department-of-Health-and-Human-Services Task-Force on Alzheimers-Disease. Neurology 34(7): 939-44 (1984).
6. [6] Ding F, Yao J, Rettberg JR, Chen S, Brinton RD. Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. PloS one 8(11): e79977 (2013).
7. [7] Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107(43): 18670-5 (2010).
8. [8] Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30(10): 1574-86 (2009).
9. [9] Boncompagni S, Moussa CEH, Levy E, Pezone MJ, Lopez JR, Protasi F, et al. Mitochondrial Dysfunction in Skeletal Muscle of Amyloid Precursor Protein-overexpressing Mice. J Biol Chem 287(24): 20534-44 (2012).
10. [10] Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349(9068): 1805-9 (1997).
11. [11] Teipel SJ, Flatz WH, Heinsen H, Bokde ALW, Schoenberg SO, Stockel S, et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain 128: 2626-44 (2005).
12. [12] Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Brit J Radiol 80: S160-S7 (2007).
13. [13] Hanyu H, Asano T, Sakurai H, Tanaka Y, Takasaki M, Abe K. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. Am J Neuroradiol 23(1): 2732 (2002).
14. [14] Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281(15): 1401-6 (1999).
15. [15] Davies P, Maloney AJF. Selective Loss of Central Cholinergic Neurons in Alzheimers-Disease. Lancet 2(8000): 1403 (1976).
16. [16] Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy Evidence of Central Cholinergic Deficits in Senile Dementia. Lancet 1(8004): 189 (1977).
17. [17] Liston DR, Nielsen JA, Villalobos A, Chapin D, Jones SB, Hubbard ST, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 486(1): 9-17 (2004).
18. [18] Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Brit Med J 331(7512): 321-3 (2005).
19. [19] Melo T, Videira RA, Andre S, Maciel E, Francisco CS, Oliveira-Campos AM, et al.Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain. J Neurochem 120(6): 998-1013 (2012).
20. [20] Mesulam M. The cholinergic lesion of Alzheimer's disease: Pivotal factor or side show? Learn Memory 11(1): 43-9 (2004).
21. [21] Massoulie J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 11(3): 130-43 (2002).
22. [22] Fishman EB, Siek GC, MacCallum RD, Bird ED, Volicer L, Marquis JK. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol 19(3): 246-52 (1986).
23. [23] Saez-Valero J, Sberna G, McLean CA, Small DH. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 72(4): 1600-8 (1999).
24. [24] Saez-Valero J, de Ceballos ML, Small DH, de Felipe C. Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neurosci Lett 325(3): 199-202 (2002).
25. [25] Garcia-Ayllon MS, Small DH, Avila J, Saez-Valero J. Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: CrossTalk with P-tau and beta-Amyloid. Front Mol Neurosci 4: 22 (2011).
26. [26] Silveyra MX, Garcia-Ayllon MS, de Barreda EG, Small DH, Martinez S, Avila J, et al. Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. Neurobiol Aging 33(3): 624e23-624e34 (2012).
27. [27] Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 122(16): 1961-9 (2001).
28. [28] Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, et al. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 31(1): 125-47 (2007).
29. [29] Coleman BA, Taylor P. Regulation of acetylcholinesterase expression during neuronal differentiation. J Biol Chem 271(8): 4410-6 (1996).
30. [30] Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287(4): 2678-88 (2012).
31. [31] Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nature reviews Neurosci 12(5): 284-96 (2011).
32. [32] Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 24(8): 1063-70 (2003).
33. [33] Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem 177(2): 75166 (1949).
34. [34] Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem 179(1): 8-18 (1989).
35. [35] Del Rio LA, Ortega MG, Lopez AL, Gorge JL. A more sensitive modification of the catalase assay with the Clark oxygen electrode. Application to the kinetic study of the pea leaf enzyme. Anal Biochem 80(2): 409-15 (1977).
36. [36] Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 233: 380-5 (1994).
37. [37] Skalska J, Piwonska M, Wyroba E, Surmacz L, Wieczorek R, Koszela-Piotrowska I, et al.A novel potassium channel in skeletal muscle mitochondria. Biochimica et biophysica acta 1777(7-8): 651-9 (2008).
38. [38] Cardoso S, Santos RX, Correia SC, Carvalho C, Santos MS, Baldeiras I, et al. Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis 49C: 1-12 (2012).
39. [39] Monteiro-Cardoso VF, Silva AM, Oliveira MM, Peixoto F, Videira RA. Membrane lipid profile alterations are associated with the metabolic adaptation of the Caco-2 cells to aglycemic nutritional condition. J Bioenerg Biomembr 46(1): 45-57 (2014).
40. [40] Bartlett GR. Phosphorus Assay in Column Chromatography. J Biol Chem 234(3): 466-8 (1959).
41. [41] Peixoto F, Vicente J, Madeira VMC. A comparative study of plant and animal mitochondria exposed to paraquat reveals that hydrogen peroxide is not related to the observed toxicity. Toxicol in vitro 18(6): 733-9 (2004).
42. [42] Kuo YM, Kokjohn TA, Watson MD, Woods AS, Cotter RJ, Sue LI, et al. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 156(3): 797-805 (2000).
43. [43] Monteiro-Cardoso VF, Oliveira MM, Melo T, Domingues MR, Moreira PI, Ferreiro E, et al.Cardiolipin Profile Changes are Associated to the Early Synaptic Mitochondrial Dysfunction in Alzheimer's Disease. J Alzheimers Dis 43(4): 1375-92 (2015).
44. [44] Gellerich FN, Deschauer M, Chen Y, Muller T, Neudecker S, Zierz S. Mitochondrial respiratory rates and activities of respiratory chain complexes correlate linearly with heteroplasmy of deleted mtDNA without threshold and independently of deletion size. Biochimica et biophysica acta 1556(1): 41-52 (2002).
45. [45] Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443(7113): 787-95 (2006).
46. [46] Schubert W, Prior R, Weidemann A, Dircksen H, Multhaup G, Masters CL, et al. Localization of Alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res 563(1-2): 184-94 (1991).
47. [47] Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, et al. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5(1): 18-29 (2009).
48. [48] Patel S, Shah RJ, Coleman P, Sabbagh M. Potential peripheral biomarkers for the diagnosis of Alzheimer's disease. Int J Alzheimers Dis 2011: 572495 (2011).
49. [49] Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3): 409-21 (2003).
50. [50] Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, et al. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci 25(5): 1219-25 (2005).
51. [51] Akaaboune M, Allinquant B, Farza H, Roy K, Magoul R, Fiszman M, et al. Developmental regulation of amyloid precursor protein at the neuromuscular junction in mouse skeletal muscle. Mol Cell Neurosci 15(4): 355-67 (2000).
52. [52] Sarantseva SV, Kislik GA, Tkachenko NA, Vasil'ev AN, Shvartsman AL. Morphological and functional abnormalities in neuromuscular junctions of Drosophila melanogaster induced by the expression of human APP gene. Tsitologiia 54(5): 421-9 (2012).
53. [53] Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64(3): 1216-23 (1995).
54. [54] Habib LK, Lee MT, Yang J. Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity. J Biol Chem 285(50): 38933-43 (2010).
55. [55] Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266(7): 4244-50 (1991).
56. [56] Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106(34): 14670-5 (2009).
57. [57] Schuh RA, Jackson KC, Schlappal AE, Spangenburg EE, Ward CW, Park JH, et al. Mitochondrial oxygen consumption deficits in skeletal muscle isolated from an Alzheimer's disease-relevant murine model. BMC Neurosci 15: 24 (2014).
58. [58] Picard M, Hepple RT, Burelle Y. Mitochondrial functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function. Am J Physiol Cell Physiol 302(4): C629-41 (2012).
59. [59] Kriketos AD, Pan DA, Sutton JR, Hoh JF, Baur LA, Cooney GJ, et al. Relationships between muscle membrane lipids, fiber type, and enzyme activities in sedentary and exercised rats. The Am J Physiol 269(5 Pt 2): R1154-62 (1995).
60. [60] Du H, Yan SS. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochimica et Biophysica Acta 1802(1): 198-204 (2010).
61. [61] Foley P. Lipids in Alzheimer's disease: A century-old story. Biochimica et Biophysica Acta 1801(8): 750-3 (2010).
62. [62] Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA. Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 50(4): 313-30 (2011).
63. [63] Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. Prog Lipid Res 45(6): 487-510 (2006).
64. [64] Fonteh AN, Chiang J, Cipolla M, Hale J, Diallo F, Chirino A, et al. Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer's disease. J Lipid Res 54(10): 2884-97 (2013).
65. [65] Yang X, Sheng W, He Y, Cui J, Haidekker MA, Sun GY, et al. Secretory phospholipase A2 type III enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. J Lipid Res 51(5): 957-66 (2010).
66. [66] Kabarowski JH, Xu Y, Witte ON. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem Pharmacol 64(2): 161-7 (2002).
67. [67] Sundaram JR, Chan ES, Poore CP, Pareek TK, Cheong WF, Shui G, et al. Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. J Neurosci 32(3): 1020-34 (2012).
68. [68] Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. Neurobiol Aging 33(4): 831 e21-31 (2012).
69. [69] Han X, Holtzman DM, McKeel DW, Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77(4): 1168-80 (2001).
70. [70] Wood PL, Mankidy R, Ritchie S, Heath D, Wood JA, Flax J, et al. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiat Neurosci 35(1): 59-62 (2010).